Eledon Pharmaceuticals Stock Profit Margin
| ELDN Stock | USD 4.07 0.22 5.71% |
Eledon Pharmaceuticals fundamentals help investors to digest information that contributes to Eledon Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Eledon Stock. The fundamental analysis module provides a way to measure Eledon Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Eledon Pharmaceuticals stock.
| Last Reported | Projected for Next Year | ||
| Net Loss | (171.08) | (179.64) |
Eledon | Profit Margin |
Eledon Pharmaceuticals Company Profit Margin Analysis
Eledon Pharmaceuticals' Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Eledon Pharmaceuticals Profit Margin | -179.64 |
Most of Eledon Pharmaceuticals' fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Eledon Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Eledon Profit Margin Driver Correlations
Understanding the fundamental principles of building solid financial models for Eledon Pharmaceuticals is extremely important. It helps to project a fair market value of Eledon Stock properly, considering its historical fundamentals such as Profit Margin. Since Eledon Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Eledon Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Eledon Pharmaceuticals' interrelated accounts and indicators.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Did you try this?
Run Price Transformation Now
Price TransformationUse Price Transformation models to analyze the depth of different equity instruments across global markets |
| All Next | Launch Module |
Eledon Pharmaceuticals ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Eledon Pharmaceuticals' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Eledon Pharmaceuticals' managers, analysts, and investors.Environmental | Governance | Social |
Eledon Fundamentals
| Return On Equity | -0.25 | ||||
| Return On Asset | -0.33 | ||||
| Current Valuation | 152.31 M | ||||
| Shares Outstanding | 59.74 M | ||||
| Shares Owned By Insiders | 0.04 % | ||||
| Shares Owned By Institutions | 42.88 % | ||||
| Number Of Shares Shorted | 960.55 K | ||||
| Price To Book | 3.02 X | ||||
| EBITDA | (42.63 M) | ||||
| Net Income | (40.33 M) | ||||
| Cash And Equivalents | 70.46 M | ||||
| Cash Per Share | 5.12 X | ||||
| Total Debt | 383 K | ||||
| Debt To Equity | 0 % | ||||
| Current Ratio | 22.22 X | ||||
| Book Value Per Share | 1.85 X | ||||
| Cash Flow From Operations | (39.53 M) | ||||
| Short Ratio | 1.45 X | ||||
| Earnings Per Share | 0.73 X | ||||
| Price To Earnings To Growth | 0.01 X | ||||
| Target Price | 12.5 | ||||
| Number Of Employees | 20 | ||||
| Beta | 0.77 | ||||
| Market Capitalization | 230 M | ||||
| Total Asset | 125.89 M | ||||
| Retained Earnings | (243.19 M) | ||||
| Working Capital | 52.23 M | ||||
| Net Asset | 125.89 M |
About Eledon Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Eledon Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eledon Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eledon Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Eledon Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Eledon Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eledon Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Eledon Stock
Moving against Eledon Stock
| 0.82 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.81 | PALI | Palisade Bio | PairCorr |
| 0.74 | INZY | Inozyme Pharma | PairCorr |
| 0.68 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.68 | PFE | Pfizer Inc Fiscal Year End 4th of February 2025 | PairCorr |
The ability to find closely correlated positions to Eledon Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Eledon Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Eledon Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Eledon Pharmaceuticals to buy it.
The correlation of Eledon Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Eledon Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Eledon Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Eledon Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Eledon Pharmaceuticals Piotroski F Score and Eledon Pharmaceuticals Altman Z Score analysis. To learn how to invest in Eledon Stock, please use our How to Invest in Eledon Pharmaceuticals guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Eledon Pharmaceuticals. If investors know Eledon will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Eledon Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 0.73 | Return On Assets (0.33) | Return On Equity (0.25) |
The market value of Eledon Pharmaceuticals is measured differently than its book value, which is the value of Eledon that is recorded on the company's balance sheet. Investors also form their own opinion of Eledon Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Eledon Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Eledon Pharmaceuticals' market value can be influenced by many factors that don't directly affect Eledon Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Eledon Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Eledon Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Eledon Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.